Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

被引：4
|
作者：
Kelley, Robin Kate
Rimassa, Lorenza
Ryoo, Baek-Yeol
Park, Joong-Won
Blanc, Jean-Frederic
Chan, Stephen Lam
Dadduzio, Vincenzo
Yau, Thomas Cheung
Sen, Suvajit
Markby, David W.
Kaldate, Rajesh
El-Khoueiry, Anthony B.
Cheng, Ann-Lii
Meyer, Tim
Abou-Alfa, Ghassan K.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Humanitas Clin & Res Ctr, Rozzano, Italy
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Natl Canc Ctr Korea, Goyang Si, South Korea
[5] Grp Hosp St Andre, Serv Hepato Gastroenterol & Oncol Digest, Bordeaux, France
[6] Chinese Univ Hong Kong, State Key Lab Oncol South China, Dept Clin Oncol, Hong Kong, Peoples R China
[7] IRCCS, Ist Oncol Veneto, Padua, Italy
[8] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[9] Exelixis Inc, Alameda, CA USA
[10] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[11] Natl Taiwan Univ Hosp, Taipei, Taiwan
[12] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[13] UCL, Canc Inst, London, England
[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.423
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
423
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
    Yau, T.
    Meyer, T.
    Kelley, R. K.
    Mangeshkar, M.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.
    Abou-Alfa, Ghassan K.
    Meyer, Tim
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Rimassa, Lorenza
    Ryoo, Baek-Yeol
    Cicin, Irfan
    Merle, Philippe
    Park, Joong-Won
    Blanc, Jean-Frederic
    Bolondi, Luigi
    Klumpen, Heinz Josef
    Chan, Stephen Lam
    Dadduzio, Vincenzo
    Hessel, Colin
    Borgman-Hagey, Anne E.
    Schwab, Gisela
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [23] Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Venerito, M.
    Kelley, R. K.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Bolondi, L.
    Chan, S. L.
    Lim, H. Y.
    Baron, A.
    Parnis, F.
    Knox, J.
    Cattan, S.
    Yau, T.
    Lougheed, J. C.
    Milwee, S.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 282 - 283
  • [24] Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
    Kelley, Robin Kate
    Ryoo, Baek-Yeol
    Merle, Philippe
    Park, Joong-Won
    Bolondi, Luigi
    Chan, Stephen Lam
    Lim, Ho Yeong
    Baron, Ari David
    Parnis, Francis
    Knox, Jennifer
    Cattan, Stephane
    Yau, Thomas Cheung
    Lougheed, Julie
    Milwee, Steven
    El-Khoueiry, Anthony
    Cheng, Ann-Lii
    Meyer, Tim
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial
    Waidmann, O.
    Abou-Alfa, G. K.
    Meyer, T.
    Cheng, A-L
    El-Khoueiry, A. B.
    Rimassa, L.
    Ryoo, B-Y
    Cicin, I
    Merle, P.
    Chen, Y. H.
    Park, J-W
    Blanc, J-F
    Bolondi, L.
    Klumpen, H-J
    Chan, S. L.
    Dadduzio, V
    Hessel, C.
    Borgman-Hagey, A. E.
    Schwab, G.
    Kelley, R. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 254 - 254
  • [26] Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.
    Abou-Alfa, Ghassan K.
    Meyer, Tim
    Cheng, Ann-Lii
    Cicin, Irfan
    Bolondi, Luigi
    Klumpen, Heinz Josef
    Chan, Stephen Lam
    Dadduzio, Vincenzo
    Milwee, Steven
    Dubey, Sarita
    Kelley, Robin Kate
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Llovet, J.
    Ricci, S.
    Mazzaferro, V.
    Hilgard, P.
    Raoul, J.
    Zeuzem, S.
    Poulin-Costello, M.
    Moscovici, M.
    Voliotis, D.
    Bruix, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.
    Abou-Alfa, Ghassan K.
    Meyer, Tim
    Cheng, Ann-Lii
    El-Khoueiry, Anthony
    Rimassa, Lorenza
    Ryoo, Baek-Yeol
    Cicin, Irfan
    Merle, Philippe
    Chen, Yen-Hsun
    Park, Joong-Won
    Blanc, Jean-Frederic
    Bolondi, Luigi
    Klumpen, Heinz Josef
    Chan, Stephen Lam
    Dadduzio, Vincenzo
    Hessel, Colin
    Borgman-Hagey, Anne E.
    Schwab, Gisela
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC)
    Miksad, R.
    Cicin, I.
    Chen, Y.
    Klumpen, H.
    Kim, S.
    Lin, Z.
    Youkstetter, J.
    Sen, S.
    Cheng, A.
    Meyer, T.
    Kelley, R.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 134 - 134
  • [30] Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis
    Llovet, J.
    Kudo, M.
    Kang, Y-K.
    Yen, C-J.
    Finn, R. S.
    Galle, P. R.
    Assenat, E.
    Motomura, K.
    Okusaka, T.
    Berg, T.
    Hsu, C-H.
    Ikeda, M.
    Hsu, Y.
    Liang, K.
    Widau, R.
    Schelman, W.
    O'Brien, L.
    Gao, L.
    Zhu, A. X.
    ANNALS OF ONCOLOGY, 2019, 30 : 293 - +
12345